Developer docs
API playgroundTry for free, no card

Search company profiles

Ethicon Endo-Surgery

Full company profile

uuid02m13ni

Namestring
Ethicon Endo-Surgery
Legal namestring
Johnson & Johnson (Ethicon Endo-Surgery operating as division of J&J MedTech)
Company typeenum
Public
Founded yearstring
-
Descriptiontext

Ethicon Endo-Surgery is a medical device division of Johnson & Johnson, operating within J&J MedTech's Surgery franchise and headquartered in Cincinnati, Ohio. It develops, manufactures, and sells surgical instruments, wound closure products, biosurgical hemostats, surgical staplers, energy-based devices, antimicrobial dressings, surgical instruments, and an emerging line of robotics and digital surgery solutions for minimally invasive and open surgical procedures. The portfolio is organized around six product categories — wound closure, biosurgery (anchored by the SURGICEL absorbable hemostat line), surgical stapling (Echelon platform), surgical energy, antimicrobial dressings (Biopatch with CHG), and surgical instruments — and is sold under more than 135 years of Johnson & Johnson surgical heritage.

The business serves a broad base of healthcare facilities and professionals across ten surgical specialties: bariatric, cardiovascular, colon and rectal, gynecology, head and neck, interventional pulmonology, orthopaedics, plastic, thoracic, and veterinary surgery. Its go-to-market is an enterprise field-sales model in which representatives provide product demonstrations, in-service training, and clinical support directly to hospitals, ambulatory surgical centers, and specialty clinics worldwide, supplemented by a multi-channel HCP education infrastructure (education library, learning programs, in-person and virtual events, research and evidence) and a phone-based technical support line. Revenue is generated through quote-based hardware sales negotiated via healthcare procurement processes, typically structured as multi-year contracts with hospital systems, with no public pricing disclosure.

As a wholly-owned division of a publicly traded parent (NYSE: JNJ), Ethicon Endo-Surgery does not raise external capital, has no independent headcount or revenue disclosure, and operates under J&J MedTech's global regulatory, manufacturing, and distribution infrastructure. Strategic activity on record includes the 2011 acquisition of SterilMed and the more recent extension of the portfolio into robotics and digital surgery solutions.

Short descriptiontext

Ethicon Endo-Surgery, a division of Johnson & Johnson MedTech, develops and sells surgical devices for minimally invasive and open procedures. Its portfolio spans wound closure, hemostats, stapling, energy platforms, antimicrobial dressings, surgical instruments, and digital solutions, serving hospitals and surgical centers across multiple specialties.

Operating statusenum
Operating
Ownership categoryenum
akta.pro rankint
HeadquartersCincinnati, United States
HQ citystring
Cincinnati
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
surgical instruments, wound closure devices, biosurgery hemostats, surgical stapling devices, antimicrobial dressings
Industry4 codes
1Open & Minimally Invasive Surgical Instruments (Handheld, Laparoscopic, MIS)
CodeHLAHADAAPrimaryYes
2Surgical Stapling, Suturing & Hemostasis (Staplers, Clips, Sealants, Tourniquets)
CodeHLAHADALPrimaryNo
3Single-Use Surgical Devices & Procedure Packs (Disposable instruments, drapes, kits)
CodeHLAHADAMPrimaryNo
4Endoscopic Therapeutic & Access Devices (Trocars, dilators, biopsy/ablation tools)
CodeHLAHADANPrimaryNo
NAICS code3 codes
  • Surgical Appliance and Supplies Manufacturing339113
  • Surgical and Medical Instrument Manufacturing339112
  • Medical Equipment and Supplies Manufacturing3391
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
Product category
Surgical Medical Devices
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Device Sales
TypeHardware Sales
Description

Ethicon Endo-Surgery generates revenue through the sale of surgical instruments, wound closure products, biosurgery solutions (hemostats), surgical stapling devices, surgical energy products, and antimicrobial dressings to hospitals, surgical centers, and healthcare facilities worldwide.

jnjmedtech.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1Medical device products sold through healthcare procurement
ModelOtherBilling cadenceMulti-year contract
Notes

Quote-based / Not publicly disclosed

jnjmedtech.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1SURGICEL
Description

Absorbable hemostat product line for surgical bleeding control

jnjmedtech.com
+1 more record
Core offering1 text field

Ethicon Endo-Surgery develops, manufactures, and sells medical devices for minimally invasive and open surgical procedures. Its portfolio spans wound closure solutions, adjunctive absorbable hemostats (including SURGICEL Powder and the SURGICEL Endoscopic Applicator), surgical stapling instruments, surgical energy platforms, antimicrobial dressings (Biopatch Protective Disk with CHG), surgical instruments, and robotics and digital surgery solutions. Products are sold to hospitals, surgical centers, and healthcare professionals across bariatric, cardiovascular, colon and rectal, gynecology, head and neck, interventional pulmonology, orthopaedics, plastic, thoracic, and veterinary surgical specialties.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Surgical complications (infections, bleeding, wound reopening) impact millions globally - the company is advancing standards for safer surgery
Product overview1 text field

Ethicon Endo-Surgery, operating under J&J MedTech, offers a comprehensive portfolio of surgical products organized into six main categories: Wound Closure (tissue sealing and healing solutions), Biosurgery (hemostatic agents including SURGICEL™ Powder Absorbable Hemostat), Surgical Stapling (instruments for tissue approximation), Surgical Energy (electrosurgical devices), Antimicrobial Dressings (including Biopatch with CHG), and Surgical Instruments. The company has over 135 years of experience driving innovations in surgical care, serving multiple surgical specialties including bariatric, cardiovascular, colon & rectal, gynecology, head & neck, interventional pulmonology, orthopaedics, plastic, thoracic, and veterinary procedures.

Product and service1 record
1SURGICEL Powder Absorbable Hemostat
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Major competitor across surgical instruments and energy devices, with overlapping presence in orthopedic and ENT surgical specialties. Stryker's instrument and power-tool lines compete directly with Ethicon's surgical instruments category.

TypeDirect peer
Description

Dominant robotic-assisted surgery platform whose da Vinci ecosystem shifts procedural volume and instrument consumption toward robotic-compatible vendors. A defining structural competitor for the long-term share of Ethicon's open and laparoscopic surgical instrument business.

TypeDirect peer
Description

Mid-cap surgical device company offering advanced energy, electrosurgery, and general surgical instruments used by the same hospital and ASC customers Ethicon targets. Direct overlap in surgical energy and instrument categories.

TypeDirect peer
Description

Direct competitor in surgical stapling, surgical energy, and minimally invasive instruments across many of the same specialties Ethicon serves. Medtronic's diversified portfolio and Hugo robotic ecosystem compete head-to-head with Ethicon's stapling and energy franchises.

TypeDirect peer
Description

Competes with Ethicon in surgical instrumentation, biosurgery, and infection-prevention products. BD's Bard acquisition and surgical platform overlap directly with Ethicon's hemostasis, wound closure, and antimicrobial dressing franchises.

TypeBroad incumbent
Description

Broader surgical and wound care incumbent with regenerative tissue and dural repair products. Comparable to Ethicon's wound closure and biosurgery categories and competes for similar hospital and specialty surgeon customers.

TypeDirect peer
Description

Private competitor focused on minimally invasive surgical devices, trocars, and wound closure products. Directly comparable portfolio overlap in laparoscopic instrumentation and stapling-adjacent categories.

TypeDirect peer
Description

Major surgical endoscopy and energy device competitor serving many of the same surgical specialties, particularly in interventional pulmonology, colorectal, and urology where Ethicon markets endoscopic applicators and energy devices.

TypeDirect peer
Description

Sells surgical instruments, ligation devices, and access products used across open and minimally invasive procedures, with overlap in general surgery, colorectal, and gynecologic specialties where Ethicon is also active.

TypeBroad incumbent
Description

Broader medical device incumbent with significant presence in orthopedic and sports medicine surgery. Overlap with Ethicon's orthopedics specialty and adjacent wound management portfolio.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment10 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ethicon Endo-Surgery

Surgical Medical Devicesethiconendosurgery.com

Ethicon Endo-Surgery, a division of Johnson & Johnson MedTech, develops and sells surgical devices for minimally invasive and open procedures. Its portfolio spans wound closure, hemostats, stapling, energy platforms, antimicrobial dressings, surgical instruments, and digital solutions, serving hospitals and surgical centers across multiple specialties.

What Ethicon Endo-Surgery does

Ethicon Endo-Surgery is a medical device division of Johnson & Johnson, operating within J&J MedTech's Surgery franchise and headquartered in Cincinnati, Ohio. It develops, manufactures, and sells surgical instruments, wound closure products, biosurgical hemostats, surgical staplers, energy-based devices, antimicrobial dressings, surgical instruments, and an emerging line of robotics and digital surgery solutions for minimally invasive and open surgical procedures. The portfolio is organized around six product categories — wound closure, biosurgery (anchored by the SURGICEL absorbable hemostat line), surgical stapling (Echelon platform), surgical energy, antimicrobial dressings (Biopatch with CHG), and surgical instruments — and is sold under more than 135 years of Johnson & Johnson surgical heritage.

The business serves a broad base of healthcare facilities and professionals across ten surgical specialties: bariatric, cardiovascular, colon and rectal, gynecology, head and neck, interventional pulmonology, orthopaedics, plastic, thoracic, and veterinary surgery. Its go-to-market is an enterprise field-sales model in which representatives provide product demonstrations, in-service training, and clinical support directly to hospitals, ambulatory surgical centers, and specialty clinics worldwide, supplemented by a multi-channel HCP education infrastructure (education library, learning programs, in-person and virtual events, research and evidence) and a phone-based technical support line. Revenue is generated through quote-based hardware sales negotiated via healthcare procurement processes, typically structured as multi-year contracts with hospital systems, with no public pricing disclosure.

As a wholly-owned division of a publicly traded parent (NYSE: JNJ), Ethicon Endo-Surgery does not raise external capital, has no independent headcount or revenue disclosure, and operates under J&J MedTech's global regulatory, manufacturing, and distribution infrastructure. Strategic activity on record includes the 2011 acquisition of SterilMed and the more recent extension of the portfolio into robotics and digital surgery solutions.

Ethicon Endo-Surgery firmographics

Firmographics
Name
Ethicon Endo-Surgery
Legal name
Johnson & Johnson (Ethicon Endo-Surgery operating as division of J&J MedTech)
Website
https://ethiconendosurgery.com
Company type
Public
Operating status
Operating
Short description
Ethicon Endo-Surgery, a division of Johnson & Johnson MedTech, develops and sells surgical devices for minimally invasive and open procedures. Its portfolio spans wound closure, hemostats, stapling, energy platforms, antimicrobial dressings, surgical instruments, and digital solutions, serving hospitals and surgical centers across multiple specialties.
Ownership category
akta.pro rank

Ethicon Endo-Surgery industry classification

Industry
Product category
Surgical Medical Devices
NAICS
Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112), Medical Equipment and Supplies Manufacturing (3391)
SIC
Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
akta.pro primary industry
Open & Minimally Invasive Surgical Instruments (Handheld, Laparoscopic, MIS) (HLAHADAA)
akta.pro secondary industries
Surgical Stapling, Suturing & Hemostasis (Staplers, Clips, Sealants, Tourniquets) (HLAHADAL), Single-Use Surgical Devices & Procedure Packs (Disposable instruments, drapes, kits) (HLAHADAM), Endoscopic Therapeutic & Access Devices (Trocars, dilators, biopsy/ablation tools) (HLAHADAN)

Keywords

  • Surgical instruments
  • Wound closure devices
  • Biosurgery hemostats
  • Surgical stapling devices
  • Antimicrobial dressings

Where Ethicon Endo-Surgery is headquartered

Location

Headquarters

HQ city
Cincinnati
HQ country
United States
HQ region
North America

Markets served

Ethicon Endo-Surgery business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Medical Device Sales: Ethicon Endo-Surgery generates revenue through the sale of surgical instruments, wound closure products, biosurgery solutions (hemostats), surgical stapling devices, surgical energy products, and antimicrobial dressings to hospitals, surgical centers, and healthcare facilities worldwide.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractMedical device products sold through healthcare procurement

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Ethicon Endo-Surgery product offering

Product offering

Core offering

Ethicon Endo-Surgery develops, manufactures, and sells medical devices for minimally invasive and open surgical procedures. Its portfolio spans wound closure solutions, adjunctive absorbable hemostats (including SURGICEL Powder and the SURGICEL Endoscopic Applicator), surgical stapling instruments, surgical energy platforms, antimicrobial dressings (Biopatch Protective Disk with CHG), surgical instruments, and robotics and digital surgery solutions. Products are sold to hospitals, surgical centers, and healthcare professionals across bariatric, cardiovascular, colon and rectal, gynecology, head and neck, interventional pulmonology, orthopaedics, plastic, thoracic, and veterinary surgical specialties.

Product overview

Ethicon Endo-Surgery, operating under J&J MedTech, offers a comprehensive portfolio of surgical products organized into six main categories: Wound Closure (tissue sealing and healing solutions), Biosurgery (hemostatic agents including SURGICEL™ Powder Absorbable Hemostat), Surgical Stapling (instruments for tissue approximation), Surgical Energy (electrosurgical devices), Antimicrobial Dressings (including Biopatch with CHG), and Surgical Instruments. The company has over 135 years of experience driving innovations in surgical care, serving multiple surgical specialties including bariatric, cardiovascular, colon & rectal, gynecology, head & neck, interventional pulmonology, orthopaedics, plastic, thoracic, and veterinary procedures.

Differentiator

Problem solved

Functional benefit

Brands

  • SURGICEL: Absorbable hemostat product line for surgical bleeding control
  • Echelon

Products and services

  • SURGICEL Powder Absorbable Hemostat

Quantifiable outcome

  • Surgical complications (infections, bleeding, wound reopening) impact millions globally - the company is advancing standards for safer surgery

Companies that use Ethicon Endo-Surgery

Customer profile

Segments10 records

Ideal customer profiles1 record

Ethicon Endo-Surgery technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Ethicon Endo-Surgery partnerships and signals

Strategic signal

Scale indicators3 records

Recent moves4 records

Expansion highlights4 records

Ethicon Endo-Surgery competitors and assessment

Company assessment

Direct peers

  • Stryker: Major competitor across surgical instruments and energy devices, with overlapping presence in orthopedic and ENT surgical specialties. Stryker's instrument and power-tool lines compete directly with Ethicon's surgical instruments category.
  • Intuitive Surgical: Dominant robotic-assisted surgery platform whose da Vinci ecosystem shifts procedural volume and instrument consumption toward robotic-compatible vendors. A defining structural competitor for the long-term share of Ethicon's open and laparoscopic surgical instrument business.
  • Conmed: Mid-cap surgical device company offering advanced energy, electrosurgery, and general surgical instruments used by the same hospital and ASC customers Ethicon targets. Direct overlap in surgical energy and instrument categories.
  • Medtronic: Direct competitor in surgical stapling, surgical energy, and minimally invasive instruments across many of the same specialties Ethicon serves. Medtronic's diversified portfolio and Hugo robotic ecosystem compete head-to-head with Ethicon's stapling and energy franchises.
  • Becton, Dickinson and Company (BD): Competes with Ethicon in surgical instrumentation, biosurgery, and infection-prevention products. BD's Bard acquisition and surgical platform overlap directly with Ethicon's hemostasis, wound closure, and antimicrobial dressing franchises.
  • Applied Medical: Private competitor focused on minimally invasive surgical devices, trocars, and wound closure products. Directly comparable portfolio overlap in laparoscopic instrumentation and stapling-adjacent categories.
  • Olympus: Major surgical endoscopy and energy device competitor serving many of the same surgical specialties, particularly in interventional pulmonology, colorectal, and urology where Ethicon markets endoscopic applicators and energy devices.
  • Teleflex: Sells surgical instruments, ligation devices, and access products used across open and minimally invasive procedures, with overlap in general surgery, colorectal, and gynecologic specialties where Ethicon is also active.

Broad incumbents

  • Integra LifeSciences: Broader surgical and wound care incumbent with regenerative tissue and dural repair products. Comparable to Ethicon's wound closure and biosurgery categories and competes for similar hospital and specialty surgeon customers.
  • Smith+Nephew: Broader medical device incumbent with significant presence in orthopedic and sports medicine surgery. Overlap with Ethicon's orthopedics specialty and adjacent wound management portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Ethicon Endo-Surgery financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ethicon Endo-Surgery leadership team

Management profile

Number of profiles

Ethicon Endo-Surgery funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ethicon Endo-Surgery M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ethicon Endo-Surgery

What does Ethicon Endo-Surgery do?

Ethicon Endo-Surgery develops, manufactures, and sells medical devices for minimally invasive and open surgical procedures. Its portfolio spans wound closure solutions, adjunctive absorbable hemostats (including SURGICEL Powder and the SURGICEL Endoscopic Applicator), surgical stapling instruments, surgical energy platforms, antimicrobial dressings (Biopatch Protective Disk with CHG), surgical instruments, and robotics and digital surgery solutions. Products are sold to hospitals, surgical centers, and healthcare professionals across bariatric, cardiovascular, colon and rectal, gynecology, head and neck, interventional pulmonology, orthopaedics, plastic, thoracic, and veterinary surgical specialties.

Is Ethicon Endo-Surgery a public or private company?

Ethicon Endo-Surgery is a public company. It is classified as public and is currently operating.

When was Ethicon Endo-Surgery founded?

Ethicon Endo-Surgery was founded in -1.

Where is Ethicon Endo-Surgery based?

Ethicon Endo-Surgery is headquartered in Cincinnati, United States, in the North America region.

How does Ethicon Endo-Surgery make money?

One revenue line is on record: medical Device Sales.

Who are Ethicon Endo-Surgery's main competitors?

Direct peers on record are Stryker, Intuitive Surgical, Conmed, Medtronic, Becton, Dickinson and Company (BD), Applied Medical, Olympus and Teleflex. Broad incumbents are Integra LifeSciences and Smith+Nephew.

Does Ethicon Endo-Surgery have an API?

No public API is recorded for Ethicon Endo-Surgery.

What industry is Ethicon Endo-Surgery in?

Ethicon Endo-Surgery's product category is Surgical Medical Devices. Its primary akta.pro industry code is HLAHADAA, Open & Minimally Invasive Surgical Instruments (Handheld, Laparoscopic, MIS), with a secondary code of HLAHADAL, Surgical Stapling, Suturing & Hemostasis (Staplers, Clips, Sealants, Tourniquets). Its NAICS code is 339113 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Law360Missed Deadline Fatal To Patient's Stapler Suit, 4th Circ. SaysThe Fourth Circuit ruled that a surgery patient's missed expert disclosure deadline ended his case against Ethicon Endo-Surgery LLC, a Johnson & Johnson subsidiary. The ruling held that the deadline was fatal to his claim of faulty staples used in his procedure.PR NewswireWorldwide Bariatric Surgery Industry to 2025 - Key Growth Drivers, Restraints and OpportunitiesResearch and Markets announced the publication of a comprehensive market research report covering the global bariatric surgery industry for services and devices from 2020 to 2025, providing historical data from 2019-2020 and compound annual growth rate projections through 2025. The report examines market segments by procedure type, device type, end-user, and region, and includes profiles of key industry players including Apollo Endosurgery Inc., Boston Scientific Corp., Ethicon Endo-Surgery, Medtronic Plc, and ReShape Lifesciences. The announcement also covers driving factors, market restraints, opportunities, competitive landscape, and the impact of COVID-19 on the bariatric surgery market.GlobeNewswireEthicon Leading Laparoscopy Device Market due to High U.S. Obesity RatesEthicon led the U.S. laparoscopy device market in 2014 with nearly 40% market share, driven by high obesity rates and rising bariatric procedures. The company dominates ultrasonic devices and avoids pricing wars, while competitors include Covidien and Olympus. Revenue from closure devices is expected to grow as bariatric procedures increase.GlobeNewswireMegadyne(R) Announces Collaboration Agreement with ETHICONMegadyne Medical Products and Ethicon Endo-Surgery announced a collaboration agreement to offer contracting solutions for U.S. customers. The combined portfolio includes monopolar and standard bipolar from Megadyne and advanced bipolar and ultrasonic energy from Ethicon. The partnership aims to simplify inventory management and provide flexible contracting options.PR NewswireEthicon Endo-Surgery Continues to Drive New Research on the Impact of Metabolic and Bariatric Surgery on Diabetes, Other DisordersEthicon Endo-Surgery is actively supporting clinical and pre-clinical research on Metabolic and Bariatric Surgery to address obesity and related metabolic disorders, with 13 studies being presented at the American Diabetes Association's 72nd Scientific Sessions in Philadelphia. The ongoing research aims to better understand the mechanisms of action in bariatric surgeries to improve interventions for conditions like type 2 diabetes. The efforts represent a significant commitment to shifting the discussion from bariatric to metabolic surgery and enhancing patient outcomes.JnjEthicon Endo-Surgery to Showcase Broadest Spectrum of Innovative Bariatric Surgical Options, Physician Best Practices and Mobile/Web-Based After-Care Patient Programs At ASMBSEthicon Endo-Surgery is showcasing its bariatric surgical solutions, including the upcoming ECHELON FLEX™ Powered ENDOPATH Stapler and a mobile version of its REALIZE mySUCCESS patient care tool, at the ASMBS 28th Annual Meeting in Orlando. The company is also sharing early findings from its Metabolic Applied Research Strategy collaboration with academic institutions to advance obesity treatment. This event highlights Ethicon's commitment to expanding patient access and improving outcomes through new technologies and digital support platforms.Imaging Technology NewsEthicon Endo-Surgery Introduces New MR Breast Biopsy DeviceEthicon Endo-Surgery has launched the Universal Mammotome MR Biopsy System, which is compatible with a wide range of breast coils and magnets, facilitating easier targeting for MR lesions. The system features a depth locking mechanism for stability and various needle lengths for effective tissue sampling, with procedures typically lasting around 30 minutes. This new device enhances capabilities in breast biopsy procedures conducted under MRI guidance.